Abstract
Studies on the uptake of radioactively-labelled 5-hydroxytryptamine (5-HT) have revealed the accumulation of this biogenic amine in a number of different tissues. In many instances this accumulation of 5-HT represents a temperature-dependent, saturable uptake process which can be inhibited by metabolic inhibitors and by certain selectively-acting compounds. These observations indicate the presence of specific carrier or transport systems involved in the active transport of 5-HT into specific tissue elements.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Maron R, Kanner B, Schuldiner S (1979): The role of a transmembrane pH gradient in 5-hydroxytryptamine uptake by synaptic vesicles from rat brain. FEBS Letts 98: 237–240.
Wilkins JA, Greenawalt JW, Huang L (1978): Transport of 5-hydroxytryptamine by dense granules from porcine platelets. J Biol Chem253: 6260–6265.
Rudnick G, Fishkes H, Nelson PJ, Schuldiner S (1980): Evidence for two distinct serotonin transport systems in platelets. J Biol Chem255: 3638–3641.
Pletscher A, Da Prada M, Berneis KH, Tranzer JP (1971): New aspects on the storage of 5-hydroxytryptamine in blood platelets. Experientia27: 993–1120.
Scherman D (1986): Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J Neurochem47: 331–339.
Darchen F, Scherman D, Laduron PM, Henry J-P (1988): Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol Pharmacol33: 672–677.
Kanner BI (1983): Bioenergetics of neurotransmitter transport. Biochim Biophys Acta726: 293–316.
Njus D, Radda GK (1978): Bioenergetic processes in chromaffin granules: a new perspective on some old problems. Biochim Biophys Acta463: 219–244.
Angelides KJ (1980): Transport of catecholamines by native and reconstituted rat heart synaptic vesicles. J Neuro chem35: 949–962.
Greene LA, Rein G (1977): Release, storage and uptake of catecholamines by a clonal cell line of nerve growth factor (NGF) responsive pheochromocytoma cells. Brain Res129: 247–263.
Da Prada M, Obrist R, Pletscher A (1975): Discrimination of monoamine uptake by membranes of adrenal chromaffin granules. Br J Pharmacol53: 257–265.
Sneddon JM (1973): Blood platelets as a model for monoamine-containing neurones. Prog Neurobiol1: 151–198.
Stahl SM, Meltzer HY (1978): A kinetic and pharmacological analysis of 5-hydroxytrypt- amine transport by human platelets and platelet storage granules: comparison with central serotonergic neurons.J Pharmacol Exp Ther205: 118–132.
Bogdanski DF, Tissari AH, Brodie BB (1970): Mechanism of transport and storage of biogenic amines. III. Effects of sodium and potassium on kinetics of 5-hydroxytryptamine and noradrenaline transport by rabbit synaptosomes. Biochim Biophys Acta219: 189–199.
Shaskan EG, Snyder SH (1970): Kinetics of serotonin accumulation into slices from rat brain. Relationship to catecholamine uptake. J Pharmacol Exp Ther175: 404–418.
Gershon MD, Jonakait GM (1979): Uptake and release of 5-hydroxytryptamine by enteric 5-hydroxytryptaminergic neurones: effects of fluoxetine (Lilly 110140) and chlorimipramine. Br J Pharmacol66: 7–9.
Suddith RL, Hutchinson HT, Haber B (1978): Uptake of biogenic amines by glial cells in culture. 1. A neuronal-like transport of serotonin. Life Sci22: 2179–2188.
Kimelberg HK (1986): Occurrence and functional significance of serotonin and catecholamine uptake by astrocytes. Biochem Pharmacol35: 2273–2281.
Gripenberg J (1976): Inhibition by reserpine, guanethidine and imipramine of the uptake of 5-hydroxytryptamine by rat peritoneal mast cells in vivo. Acta Physiol Scand 96: 407–416.
Bosin TR, Lahr PD (1981): Mechanisms influencing the disposition of serotonin in mouse lung. Biochem Pharmacol30: 3187–3193.
Raisman R, Langer SZ (1983): Specific high affinity [3H]imipramine binding sites in rat lung are related with a non-neuronal uptake site for serotonin. Eur J Pharmacol94: 345–348.
Stahl SM (1977): The human platelet: a diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Arch Gen Psychiat 34: 509–516.
Segonzac A, Tateishi T, Langer SZ (1984): Saturable uptake of [3H]tryptamine in rabbit platelets is inhibited by 5-hydroxytryptamine uptake blockers. Naunyn-Schmiedeberg’s Arch Pharmacol328: 33–37.
Ross SB, Ask AL (1980): Structural requirements for uptake into serotonergic neurons. Acta Pharmacol Toxicol46: 270–277.
Da Prada M, Cesura AM, Launay JM, Richards JG (1988): Platelets as a model for neurones. Experientia44: 115–126.
Thoa NB, Ecclestone D, Axelrod J (1969): The accumulation of 14C-serotonin in the guinea-pig vas deferens. J Pharmacol Exp Ther169: 68–73.
Lindström P, Sehlin J, Täljedal I-B (1980): Characteristics of 5-hydroxytryptamine transport in pancreatic islets. Br J Pharmacol68: 773–778.
Verbeuren TJ, Jordaens FH, Herman AG (1983): Accumulation and release of [3H]5- hydroxytryptamine in saphenous veins and cerebral arteries of the dog. J Pharmacol Exp Ther226: 579–588.
Ducis I, Di Stefano V (1980): Characterization of serotonin uptake in isolated pinealocyte suspensions. Mol Pharmacol18: 447–454.
Talvenheimo J, Nelson PJ, Rudnick G (1979): Mechanism of imipramine inhibition of platelet 5-hydroxytryptamine transport. J Biol Chem254: 4631–4635.
Nelson PJ, Rudnick G (1982): The role of chloride ion in platelet serotonin transport. J Biol Chem257: 6151–6155.
Ross SB, Helder D (1977): Efflux of 5-hydroxytryptamine from synaptosomes of rat cerebral cortex. Acta Physiol Scand99: 27–36.
Keyes SR, Rudnick G (1982): Coupling of transmembrane proton gradients to platelet serotonin transport. J Biol Chem257: 1172–1176.
Jauch P, Läuger P (1986): Electrogenic properties of the sodium-alanine cotransporter in pancreatic acinar cells: II. Comparison with transport models. J Memb Biol94: 117–127.
Jauch P, Läuger P (1988): Kinetics of the Na+/alanine cotransporter in pancreatic acinar cells. Biochim Biophys Acta939: 179–188.
Hytell J (1982): Citalopram: pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuro-Psychopharmacol & Biol Psychiat6: 277–295.
Haefely W, Schaffner R, Burkard WP, Da Prada M, Kellar HH, Pole P, Richards JG (1978): Ro 11-2465, a potent and selective inhibitor of 5-hydroxytryptamine uptake. 11th C.I.N.P. Congress, Vienna, July abstracts p. 95.
Thomas DR, Nelson DR, Johnson AM (1987): Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology93: 193–200.
Scatton B, Claustre Y, Graham D, Dennis T, Serrano A, Arbilla S, Pimoule C, Schoemaker H, Bigg D, Langer SZ (1988): SL 81.0385: a novel selective and potent serotonin uptake inhibitor. Drug Dev Res12: 29–40.
Le Fur G, Uzan A (1977): Effects of 4-(3-indolyl-alkyl)-piperidine derivatives on uptake and release of noradrenaline, dopamine and 5-hydroxytryptamine in rat brain synaptosomes, rat heart and human blood platelets. Biochem Pharmacol26: 497–503.
Stark P, Fuller RW, Wong DT (1985): The pharmacologic profile of fluoxetine. J Clin Psychiat46: 7–13.
Claassen V (1983): Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol 15: 349S–355S.
Graham D, Langer SZ (1988): The neuronal sodium-dependent serotonin transporter: studies with [3H]imipramine and [3H]paroxetine, pp. 367–391 in: Osborne NN, Hamon M (eds), Neuronal Serotonin. John Wiley and Sons Ltd.
Langer SZ, Moret C, Raisman R, Dubocovich ML, Briley MS (1980): High affinity [3H]imipramine binding in rat hypothalamus is associated with the uptake of serotonin but not norepinephrine. Science210: 1133–1135.
Langer SZ, Briley M, Raisman R, Henry J-F, Morselli PL (1980): Specific [3H]imipra- mine binding in human platelets: influence of age and sex. Naunyn-Schmiedeberg’s Arch Pharmacol313: 189–194.
Habert E, Graham D, Tahraoui L, Claustre Y, Langer SZ (1985): Characterization of [3H] paroxetine binding to rat cortical membranes. Eur J Pharmacol118: 107–114.
Segonzac A, Schoemaker H, Langer SZ (1987): Temperature-dependence of drug interaction with the platelet 5-HT transporter: a clue to the imipramine selectivity paradox. J Neurochem48: 331–339.
Habert E, Graham D, Langer SZ (1986): Solubilization and characterization of the 5-hydroxytryptamine transporter complex from rat cerebral cortical membranes. Eur J Pharmacol122: 197–204.
Goodwin FK, Post RM (1983): 5-hydroxytryptamine and depression: a model for the interaction of normal variance with pathology. Br J Clin Pharmacol 15: 393S–405S.
Shopsin B, Gershon S, Goldstein M, Friedman E, Wilk S (1975): The use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol Commun1: 239–249.
Shopsin B, Friedman E, Gershon S (1976): Parachlorophenylalanine reversal of trancypromine effects in depressed patients. Arch Gen Psychiat33: 811–819.
Stark P, Hardison CD (1985): A review of multi-centered outpatient imipramine and placebo controlled studies of fluoxetine in the treatment of major depressive disorders. J Clin Psychiatry46: 53 - 58.
Penfield P, Ward A (1986): Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32: 313 –334.
Anderson J, Bech P, Benjaminsen S et al. (1986): Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology90: 131 - 138.
Simpson RJ, Lawton DJ, Watt MH, Tiplady B (1981): Effect of zimelidine, a new antidepressant, on appetite and body weight. Br J Clin Pharmacol11: 96–98.
Smedgegaard J, Christiansen P, Skrumsager B (1981): Treatment of obesity by femoxetine, a selective 5-HT uptake inhibitor. Int J Obesity5: 377–378.
Ferguson JM (1986): Fluoxetine induced weight loss in non-depressed overweight humans. Alimentazione Nutrizione Metabolismo7: (2) 19.
Naranjo CA, Sellers EM, Roach CA, Woodley DV, Sanchez-Craig M, Sykora K (1984): Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clin Pharmacol Ther35: 373–381.
Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Sanchez-Craig M, Sykora K (1987): The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 41: 266–214.
Flood JF, Cherkin A (1987): Fluoxetine enhances memory processing in mice. Psychopharmacology93: 36–43.
Altman HJ, Nordy DA, Ögen SV (1984): Role of serotonin in memory: facilitation by alaproclate and zimelidine. Psychopharmacology84: 496–502.
Gabizon R, Schuldiner S (1985): The amine transporter from bovine chromaffin granules. J Biol Chem 260: 3001 -3005.
De Lean A, Munson PJ, Rodbard D (1978): Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose- response curves. Am J Physiol 235: E97–El02.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Graham, D., Langer, S.Z. (1990). 5-Hydroxytryptamine transport systems. In: Saxena, P.R., Wallis, D.I., Wouters, W., Bevan, P. (eds) Cardiovascular Pharmacology of 5-Hydroxytryptamine. Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine, vol 106. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0479-8_2
Download citation
DOI: https://doi.org/10.1007/978-94-009-0479-8_2
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6701-0
Online ISBN: 978-94-009-0479-8
eBook Packages: Springer Book Archive